Docetaxel distribution following intraperitoneal administration in mice

Area of Science:

• Oncology
• Pharmacology
• Biomaterials

Background:

• Intraperitoneal (IP) chemotherapy with taxanes shows promise for localized peritoneal cancers.
• A novel injectable hydrogel formulation, PoLigel, was developed for sustained IP delivery of docetaxel (DTX).
• Previous studies demonstrated PoLigel's significant efficacy in murine ovarian cancer models compared to Taxotere®.

Purpose of the Study:

• To compare the tissue distribution and pharmacokinetics of DTX administered IP via PoLigel versus the FDA-approved Taxotere® formulation.
• To elucidate the relationship between drug distribution and therapeutic efficacy.

Main Methods:

• PoLigel was prepared by blending a chitosan derivative, egg phosphatidylcholine, and lauric aldehyde with DTX.
• DTX concentrations were measured in plasma and various tissues (heart, liver, spleen, stomach, intestine, kidney, peritoneal muscle) over five days post-IP administration in mice.
• Both PoLigel and Taxotere® formulations were evaluated.

Main Results:

• Sustained DTX plasma levels were observed with PoLigel (0.06 ug/ml ± 0.01/day) for five days, unlike Taxotere® which showed no detectable levels after three days.
• Five days post-administration, PoLigel resulted in detectable DTX in all tested tissues and plasma, whereas Taxotere® only showed levels in the intestine, stomach, and peritoneal muscle.
• DTX concentrations in the peritoneal cavity were significantly higher (200-fold) with PoLigel compared to plasma concentrations.

Conclusions:

• The PoLigel formulation significantly increases DTX retention in tissues and plasma, providing sustained drug levels compared to Taxotere®.
• The enhanced and sustained DTX levels in the peritoneal cavity achieved with PoLigel likely contribute to its improved efficacy observed in prior studies.
• PoLigel represents a promising strategy for improving the therapeutic outcomes of IP chemotherapy for peritoneal malignancies.